What Nurses Need to Know: New data on implementing the Prospera™ donor-derived cell-free DNA test into your kidney transplant surveillance

January 29, 2024

Dive into the latest data showcasing the Prospera™ test as a proven leading indicator of rejection - a critical component to any transplant care team's rejection monitoring toolkit.

What Nurses Need to Know: New data on implementing the Prospera™ donor-derived cell-free DNA test into your kidney transplant surveillance

Cell-free DNA testing: An alternative option to surveillance biopsy in children

JoDee & Daniel’s story

Clinician’s guide to Renasight results

A Roundtable Conversation on Post-transplant Care

Accelerating kidney disease clinical trials: The power of data driven patient recruitment

Prospera Heart Pediatric Brochure

Dr Bunnapradist discusses his authorship in the ProActive Study and unmet need in seemingly stable populations / subclinical rejection

Prospera Heart Peds MD Brochure

What is the difference between this test and our regular or routine labs

Why does monitoring matter

What is the process to use Natera's Prospera test

Two thresholds, one powerful solution: Combining the quantity and fraction of dd-cfDNA in a single blood test to improve the accuracy of non

Dr. Rao DQS case studies

Dr. Lampert DQS case studies

Brian's Story: Surveilling with Prospera caught rejection early and saved his kidney

Prospera Patient Portal Guide SPANISH

Prospera Kidney- Patient Brochure- SPANISH

Prospera Kidney- Billing Guide SPANISH

Video para Pacientes de Prospera

ASN Kidney Week 2024